Key facts
- EndoRobotics’s last known valuation is $16.0M (Aug 2021).
- It has raised $35.1M; the latest was Later Stage VC ($22.3M) in Dec 2025.
- Notable investors include Tech Incubator Program for Startup, Mirae Asset Capital, Korea Technology Finance, Partners Investment, Premier Partners — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for EndoRobotics
- ·The full record, as it builds
Funding rounds
No funding rounds for EndoRobotics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EndoRobotics
Manufacturer of endoscopic robotic medical equipment intended to support non-invasive therapeutic procedures in gastroenterology. The company attaches robotic arms to flexible endoscopes, facilitating precise tissue dissection, suturing, and lesion removal within the gastrointestinal tract, enabling healthcare providers to perform minimally invasive surgeries that reduce recovery time, avoid external scarring, and improve patient outcomes in digestive disease treatment.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 46
- Website
- endorobo.com/
- Ownership
- Privately Held (backing)
EndoRobotics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EndoRobotics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EndoRobotics in its N-PORT filings yet. We sweep new filings monthly.